TARA vs. GNLX

Last updated Jun 5, 2026

TARA (Protara Therapeutics, Inc.) and GNLX (Genelux Corporation) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, TARA returned 14.34%/yr vs -52.16%/yr for GNLX. At a 0.15 correlation, their price movements are largely independent.

Performance

TARA vs. GNLX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Protara Therapeutics, Inc. (TARA) and Genelux Corporation (GNLX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TARA achieves a -17.26% return, which is significantly higher than GNLX's -29.36% return.

TARA

• 1D: 4.50%
• 1M: -18.48%
• YTD: -17.26%
• 6M: -35.81%
• 1Y: 36.96%
• 3Y*: 14.34%
• 5Y*: -15.42%
• 10Y*: -32.55%

GNLX

• 1D: 2.67%
• 1M: 11.19%
• YTD: -29.36%
• 6M: -33.76%
• 1Y: 25.71%
• 3Y*: -52.16%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

TARA vs. GNLX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
TARA Protara Therapeutics, Inc.	-17.26%	0.95%	181.58%	-40.66%
GNLX Genelux Corporation	-29.36%	84.75%	-83.15%	127.80%

Correlation

The correlation between TARA and GNLX is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.27
Correlation (3Y) Calculated over the trailing 3-year period	0.16
Correlation (All Time) Calculated using the full available price history since Jan 27, 2023	0.15

The correlation between TARA and GNLX shifts across timeframes, from 0.15 (all time) to 0.27 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap TARA : $253.75M GNLX : $135.98M
EPS TARA : -$1.35 GNLX : -$0.85
PB Ratio TARA : 1.40 GNLX : 5.93
Total Revenue (TTM) TARA : $0.00 GNLX : $8.00K
Gross Profit (TTM) TARA : -$181.00K GNLX : -$283.00K
EBITDA (TTM) TARA : -$66.86M GNLX : -$24.96M

Return for Risk

TARA vs. GNLX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TARA

TARA Risk / Return Rank: 59
TARA Sharpe Ratio Rank: 57
TARA Sortino Ratio Rank: 60
TARA Omega Ratio Rank: 59
TARA Calmar Ratio Rank: 59
TARA Martin Ratio Rank: 59

GNLX

GNLX Risk / Return Rank: 52
GNLX Sharpe Ratio Rank: 52
GNLX Sortino Ratio Rank: 54
GNLX Omega Ratio Rank: 57
GNLX Calmar Ratio Rank: 50
GNLX Martin Ratio Rank: 48

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TARA vs. GNLX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Protara Therapeutics, Inc. (TARA) and Genelux Corporation (GNLX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TARA	GNLX	Difference
Sharpe ratio: Return per unit of total volatility	0.46	0.30	+0.17
Sortino ratio: Return per unit of downside risk	1.25	1.01	+0.24
Omega ratio: Gain probability vs. loss probability	1.16	1.15	+0.01
Calmar ratio: Return relative to maximum drawdown	0.84	0.36	+0.48
Martin ratio: Return relative to average drawdown	1.78	0.56	+1.23
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TARA vs. GNLX - Sharpe Ratio Comparison

The current TARA Sharpe Ratio is 0.46, which is higher than the GNLX Sharpe Ratio of 0.30. The chart below compares the historical Sharpe Ratios of TARA and GNLX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	TARA	GNLX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.46	0.30	+0.17
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.19	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.36	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.37	-0.17	-0.20

Drawdowns

TARA vs. GNLX - Drawdown Comparison

The maximum TARA drawdown since its inception was -99.86%, roughly equal to the maximum GNLX drawdown of -95.74%. Use the drawdown chart below to compare losses from any high point for TARA and GNLX.

Drawdown Indicators

	TARA	GNLX	Difference
Max Drawdown Largest peak-to-trough decline	-99.86%	-95.74%	-4.12%
Max Drawdown (1Y) Largest decline over 1 year	-44.18%	-72.09%	+27.91%
Max Drawdown (3Y) Largest decline over 3 years	-66.46%	-95.74%	+29.28%
Max Drawdown (5Y) Largest decline over 5 years	-89.53%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-99.75%	—	—
Current Drawdown Current decline from peak	-99.45%	-91.89%	-7.56%
Average Drawdown Average peak-to-trough decline	-85.09%	-73.14%	-11.95%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.78%	46.39%	-25.61%

Volatility

TARA vs. GNLX - Volatility Comparison

Protara Therapeutics, Inc. (TARA) has a higher volatility of 19.57% compared to Genelux Corporation (GNLX) at 17.83%. This indicates that TARA's price experiences larger fluctuations and is considered to be riskier than GNLX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TARA	GNLX	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.57%	17.83%	+1.74%
Volatility (6M) Calculated over the trailing 6-month period	57.93%	53.81%	+4.12%
Volatility (1Y) Calculated over the trailing 1-year period	80.01%	87.04%	-7.03%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	80.93%	110.91%	-29.98%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	91.23%	110.91%	-19.68%

Dividends

TARA vs. GNLX - Dividend Comparison

Neither TARA nor GNLX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both TARA and GNLX in my portfolio?

TARA and GNLX have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, TARA or GNLX?

TARA has higher volatility (19.57%) compared to GNLX (17.83%). In terms of maximum drawdown, TARA dropped -99.86% vs GNLX's -95.74%.

Which has better risk-adjusted returns?

TARA currently has the higher Sharpe Ratio (0.46 vs 0.30), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.